PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



cvfile 0023229.pdf


Preview of PDF document cvfile-0023229.pdf

Page 1 2 3 4 5 6

Text preview


UCSD CANCER CENTER
SAN DIEGO, CA
2006. 9 – 2007. 12 POSTDOC FELLOWSHIP
SYDNEY KIMMEL CANCER CENTER
SAN DIEGO, CA
2008. 1 – 2008. 2 CLINICAL ASSITANT PROFESSOR
DEPARTMENT OF HEMATOLOGY AND ONCOLOGY
SAMSUNG MEDICAL CENTER
SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE
SEOUL, KOREA
2008. 3 – present ASSOCIATE PROFESSOR
DEPARTMENT OF HEMATOLOGY AND ONCOLOGY
SAMSUNG MEDICAL CENTER
SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE
SEOUL, KOREA
MEMBERSHIP – AMERICAN SOCIETY OF CLINICAL ONCOLOGY
AMERICAN SOCIETY OF HEMATOLOGY
THE KOREAN MEDICAL ASSOCIATION
THE KOREAN ASSOCIATION OF INTERNAL MEDICINE
THE KOREAN CANCER ASSOCIATION
THE KOREAN SOCIETY FOR HOSPICE & PALLIATIVE CARE
THE KOREAN SOCIETY OF HEMATOLOGY
KOREAN CANCER STUDY GROUP
KOREAN ASSOCIATION FOR CLINICAL ONCOLOGY
CLINICAL TRIAL EXPERIENCE
- A Phase III, randomized, Double-blind, Placebo-Controlled, Multicenter study to evaluate the
efficacy and safety of Bevacizumab, and Associcated Biomarkers, in combination with Paclitaxel
compared with Paclitaxel plus Placebo as 1st line Treatment of patients with HER2-Negative
Metastatic Breast cancer, sponsored by Roche, 2013, Principal investigator [GO25632]
- A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients with
Metastatic or Recurrent Breast Cancer, sponsored by Nippon Kayaku, 2013, Principal investigator
[NK105]
- A Phase 3 Open-label, Randomized, Multicenter study of NKTR-102 versus Treatment of
physician’s choice(TPC) in patients with locally recurrent or metastatic breast cancer previously
treated with an anthracycline, a taxane, and capecitabine, sponsored by Nektar, 2013,
sub-investigator [BEACON]
- A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exmestane, Compared to
Ridaforolimus, Dalotuzumab and Exmestane in High Proliferation Estrogen Receptor Positive
Breast Cancer Patients. sponsored by MSD, 2012, Principal investigator[MK8669-064]

-2-